Answers are grounded in this paper and cite their sources.
Retrospective cohort study investigates infection outcomes in hospitalized patients, suggesting improved mortality with specialist evaluation.
Burkholderia cepacia (BC) infections represent a significant clinical challenge in hospital environments, especially in critically ill or immunocompromised patients. The high intrinsic resistance of this bacterium to multiple antimicrobials, in addition to the difficulty of standardization and reliability of susceptibility tests—including without determination of breakpoints by BrCAST—are associated with high mortality rates and prolonged length of stay. This study aims to evaluate clinical outcomes and the impact of infectious disease specialist assessment in 45 hospitalized patients with isolation of BC in biological samples between January 2020 and June 2025. Retrospective cohort study including 45 patients with positive culture for BC in clinical samples. Demographic data, SOFA score, initial antimicrobial regimen, and clinical outcome were collected. Treatment adequacy was defined by agreement with recommendations from international guidelines and the standardized susceptibility test result available at the time of pathogen isolation. Primary outcomes: mortality attributable to the infection event and overall in-hospital mortality. Statistical analyses involved logistic regression and Kaplan–Meier. Of the 45 cases analyzed, 32 represented infection events, of which 87% occurred in the ICU and 13% in a medical ward. Overall mortality attributable to the infection event was 40% and overall in-hospital mortality was 62.5%. There was a difference in the approach to infection events depending on the site of pathogen isolation: 81% of patients with positive blood cultures were evaluated by the infectious diseases team, with therapeutic adequacy in 94% of patients, whereas 10% of patients with respiratory samples positive for BC were evaluated by the infectious diseases team, resulting in 56.5% inadequacy of regimens. Among patients with respiratory samples positive and therapeutic inadequacy, mortality reached 33%. BC infection is a high-mortality event. Infectious disease specialist assessment increases therapeutic adequacy and may have an impact on reducing mortality.
No takes yet. Share an insight, caveat, or question.
Jucá et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: